Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy and Erlotinib in Oligometastatic Non-squamous NSCLC
NCT01796288Phase 2Unknown
- Sponsor
- Wu Jieping Medical Foundation
- Start
- Oct 2012
- Primary completion
- Apr 2016
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of erlotinib in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Wu Jieping Medical Foundation. Status: unknown.
02
Drugs
erlotinib
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT01796288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01796288.